Real‐world experience of off‐label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna
Aimilios Lallas, Elvira Moscarella, Harald Kittler, Caterina Longo, L. Thomas, Iris Zalaudek, Αthanassios Kyrgidis, Sofia‐Magdalini Manoli, Nicola di Meo, Chryssoula Papageorgiou, Zoé Apalla, Giuseppe Argenziano
Abstract
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Topics & Concepts
ImiquimodLentigo malignaMedicineDermatologyAdjuvant therapyAdjuvantSurgeryGeneral surgeryOncologyMelanomaChemotherapyCancer researchNonmelanoma Skin Cancer StudiesCutaneous Melanoma Detection and ManagementMyasthenia Gravis and Thymoma